ccc_R08 是一种无细胞毒性且口服有效的cccDNA 抑制剂，可降低 HBV 感染小鼠肝脏中的 cccDNA 水平。ccc_R08 可用于 HBV病毒 (乙型肝炎病毒) 感染的研究。
| 生物活性 | ccc_R08 is a non-cytotoxic and orally activecccDNA inhibitorthat reduces cccDNA levels in the liver of HBV-infected mice. ccc_R08 can be used in the study ofHBVvirus (hepatitis B virus)infection[1][2]. |
| IC50& Target | |
体外研究
(In Vitro) | ccc_R08 (0.3, 1.0, 3.2, 10, 32 μM; 5 days) 显著降低 HepDES19 细胞中 cccDNA、无蛋白 RC-DNA 和双链线性 DNA (DL-DNA) 的水平[1]。
ccc_R08 (0-100 μM) 以剂量依赖性方式降低 HepDES19 细胞的胞外 HBeAg 水平，IC50约为 0.1 μM[1]。
Western Blot Analysis[1] | Cell Line: | HepDES19 cells | | Concentration: | 0.3, 1.0, 3.2, 10, 32 μM | | Incubation Time: | 5 days | | Result: | Reduced the level of cccDNA, protein-free RC-DNA, and double stranded linear DNA (DL-DNA). |
|
体内研究
(In Vivo) | ccc_R08 (20 mg/kg; p.o.; twice per day for 2 weeks) 从 HBVcircle 小鼠肝脏中清除 cccDNA[1]。
ccc_R08 (10, 15, 20, 30 mg/kg; p.o.; twice per day for 2 weeks) 以剂量依赖性方式显着降低 pgRNA 的血清水平，并且 pgRNA 的降低与不同剂量下肝脏 cccDNA 的降低定量相关[1]。
| Animal Model: | HBVcircle mouse model[1]. | | Dosage: | 20 mg/kg | | Administration: | Oral administration; twice per day for 2 weeks | | Result: | Led to the clearance of cccDNA from HBVcircle mouse livers. |
| Animal Model: | HBVcircle mouse model[1]. | | Dosage: | 10, 15, 20, 30 mg/kg | | Administration: | Oral administration; twice per day for 42 days | | Result: | Led to a sustained reduction in the serum levels of pgRNA. |
|
| 分子量 | |
| Formula | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com